T helper type 17 cell differentiation pathway (Th17 differentiation pathway)

The **T helper type 17 cell differentiation pathway** describes the stepwise molecular events and regulatory mechanisms by which naïve CD4+ T cells are converted into Th17 cells—a unique T cell subset defined by their ability to produce IL-17A and other effector cytokines. This pathway begins with the stimulation of the T cell receptor by antigen presentation in the context of specific cytokines: chiefly transforming growth factor-beta (TGF-β) and interleukin-6 (IL-6). These signals activate the key transcription factor **RORγt**, supported by **STAT3**, **BATF**, and **IRF4**, driving the expression of Th17 hallmark cytokines (IL-17A, IL-17F, IL-21, IL-22). Cytokines such as IL-21 and IL-23 further amplify and stabilize the phenotype, whereas other signals (IL-4, IFN-γ) inhibit the commitment to this lineage. Th17 cells play pivotal roles in maintaining mucosal barrier integrity and immune defense against extracellular bacteria and fungi but, when dysregulated, contribute to chronic inflammation and autoimmunity. Therapeutics targeting molecules within this pathway (not the pathway itself) are in development for autoimmune and inflammatory diseases[1][2][3][4][5][6][7]. **Note:** For drug or therapeutic targeting, more specific molecules within this pathway—such as "Retinoic acid receptor-related orphan receptor gamma t (RORγt)" or "Interleukin-23 receptor (IL-23R)"—should be used. The pathway itself is not a canonical therapeutic target.

Other names

Th17 differentiationTh17 cell developmentT helper 17 cell lineage commitment